XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2024 and June 30, 2023 is as follows (in thousands):
Six Months Ended June 30, 2024Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2024
$15,755 $2,557 $300 68,700 
Payment(12,400)
Change in fair value of contingent consideration liabilities (934)Research and development75 — 3,200 Selling, general and administrative
Balance as of June 30, 202414,821 2,632 300 59,500 
Short-Term $8,244 $— $— $19,200 Accrued expenses and other current liabilities
Long-Term6,577 2,632 300 40,300 Other liabilities
Total14,821 2,632 300 59,500 
Six Months Ended June 30, 2023Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACellSurgical Innovations Associates (SIA), Inc.Location in Financial Statements
Balance as of January 1, 2023
$12,895 $230 $3,700 $57,607 
Change in fair value of contingent consideration liabilities3,081 Research and development(2,200)5,200 Selling, general and administrative
Balance as of June 30, 2023
$15,976 $230 $1,500 $62,807 
Short-Term $4,389 $— $— $12,700 Accrued expenses and other current liabilities
Long-Term11,587 230 1,500 50,107 Other liabilities
Total15,976 230 1,500 62,807